Skip to main content

Advertisement

SpringerLink
Log in

Pulmonary Hypertension in Women: What Does the Cardiologist Need to Know?

  • Women and Heart Disease (E. Jackson, Section Editor)
  • Published:
Current Cardiovascular Risk Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Our goal is to review the epidemiology, diagnosis, and management of PH focusing on how this condition affects women.

Recent Findings

PH is a broad term used to describe a group of medical conditions presenting with elevated pressures in the pulmonary circulation. A subgroup, PAH, is of great importance as many medical therapies have been developed and clinical outcomes have improved substantially when compared with historical data. PAH is more predominant in women and is an under recognized medical condition.

Summary

PAH is a progressive condition for which many medical therapies are now available. Further research is needed to evaluate the effects of PH-specific medications on other forms of PH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance. •• Of major importance

  1. D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343–9.

    Article  PubMed  Google Scholar 

  2. McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62(25 Suppl):D51–9. These are the 2015 ESC/ERS guideline in pulmonary hypertension. This article overviews the different forms of pulmonary hypertension and thoroughly describes de medical therapy available for pulmonary arterial hypertension.

    Article  PubMed  Google Scholar 

  3. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46(4):903–75.

    Article  CAS  PubMed  Google Scholar 

  4. Maron BA, Hess E, Maddox TM, Opotowsky AR, Tedford RJ, Lahm T, et al. Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the Veterans affairs clinical assessment, reporting, and tracking program. Circulation. 2016;133(13):1240–8.

    Article  PubMed  Google Scholar 

  5. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D42–50.

    Article  PubMed  Google Scholar 

  6. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D34–41.

    Article  PubMed  Google Scholar 

  7. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376–87.

    Article  PubMed  Google Scholar 

  8. Cogan JD, Vnencak-Jones CL, Phillips 3rd JA, Lane KB, Wheeler LA, Robbins IM, et al. Gross BMPR2 gene rearrangements constitute a new cause for primary pulmonary hypertension. Genet Med. 2005;7(3):169–74.

    Article  CAS  PubMed  Google Scholar 

  9. Machado RD, Pauciulo MW, Thomson JR, Lane KB, Morgan NV, Wheeler L, et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet. 2001;68(1):92–102.

    Article  CAS  PubMed  Google Scholar 

  10. Gurtner HP. Aminorex and pulmonary hypertension. A review. Cor Vasa. 1985;27(2–3):160–71.

    CAS  PubMed  Google Scholar 

  11. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;335(9):609–16.

    Article  CAS  PubMed  Google Scholar 

  12. Gomez-Sanchez MA, Saenz de la Calzada C, Gomez-Pajuelo C, Martinez-Tello FJ, Mestre de Juan MJ, James TN. Clinical and pathologic manifestations of pulmonary vascular disease in the toxic oil syndrome. J Am Coll Cardiol. 1991;18(6):1539–45.

    Article  CAS  PubMed  Google Scholar 

  13. Albertson TE, Walby WF, Derlet RW. Stimulant-induced pulmonary toxicity. Chest. 1995;108(4):1140–9.

    Article  CAS  PubMed  Google Scholar 

  14. Montani D, Bergot E, Gunther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128–37.

    Article  CAS  PubMed  Google Scholar 

  15. Savale L, Sattler C, Gunther S, Montani D, Chaumais MC, Perrin S, et al. Pulmonary arterial hypertension in patients treated with interferon. Eur Respir J. 2014;44(6):1627–34.

    Article  CAS  PubMed  Google Scholar 

  16. Coghlan JG, Denton CP, Grunig E, Bonderman D, Distler O, Khanna D, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73(7):1340–9.

    Article  PubMed  Google Scholar 

  17. Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest. 1991;100(5):1268–71.

    Article  CAS  PubMed  Google Scholar 

  18. Sitbon O, Lascoux-Combe C, Delfraissy JF, Yeni PG, Raffi F, De Zuttere D, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med. 2008;177(1):108–13.

    Article  PubMed  Google Scholar 

  19. Degano B, Guillaume M, Savale L, Montani D, Jais X, Yaici A, et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS. 2010;24(1):67–75.

    Article  PubMed  Google Scholar 

  20. Swanson KL, Wiesner RH, Nyberg SL, Rosen CB, Krowka MJ. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant. 2008;8(11):2445–53.

    Article  CAS  PubMed  Google Scholar 

  21. Humbert M, Sitbon O, Yaici A, Montani D, O’Callaghan DS, Jais X, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010;36(3):549–55.

    Article  CAS  PubMed  Google Scholar 

  22. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53(13):1119–26.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Seeger W, Adir Y, Barbera JA, Champion H, Coghlan JG, Cottin V, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62(25 Suppl):D109–16.

    Article  PubMed  Google Scholar 

  24. Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350(22):2257–64.

    Article  CAS  PubMed  Google Scholar 

  25. Mizoguchi H, Ogawa A, Munemasa M, Mikouchi H, Ito H, Matsubara H. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv. 2012;5(6):748–55.

    Article  PubMed  Google Scholar 

  26. Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2011;139(1):128–37. This article contrasts different registries and explains how pulmonary hypertension affects different populations.

    Article  PubMed  Google Scholar 

  27. Hemnes AR, Kiely DG, Cockrill BA, Safdar Z, Wilson VJ, Al Hazmi M, et al. Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute. Pulm Circ. 2015;5(3):435–65. Hemnes et al. summarize the impact of pulmonary hypertension during pregnancy and give specific recommendation on how to prevent and manage this condition.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Executive summary: heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129(3):399–410.

    Article  PubMed  Google Scholar 

  29. Nieminen MS, Harjola VP, Hochadel M, Drexler H, Komajda M, Brutsaert D, et al. Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. Eur J Heart Fail. 2008;10(2):140–8.

    Article  PubMed  Google Scholar 

  30. Hoekstra T, Jaarsma T, van Veldhuisen DJ, Hillege HL, Sanderman R, Lesman-Leegte I. Quality of life and survival in patients with heart failure. Eur J Heart Fail. 2013;15(1):94–102.

    Article  PubMed  Google Scholar 

  31. O’Meara E, Clayton T, McEntegart MB, McMurray JJ, Pina IL, Granger CB, et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007;115(24):3111–20.

    Article  PubMed  Google Scholar 

  32. Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, O’Meara E, et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail. 2014;7(5):740–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Lam CS, Borlaug BA, Kane GC, Enders FT, Rodeheffer RJ, Redfield MM. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation. 2009;119(20):2663–70.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Kjaergaard J, Akkan D, Iversen KK, Kjoller E, Kober L, Torp-Pedersen C, et al. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol. 2007;99(8):1146–50.

    Article  PubMed  Google Scholar 

  35. Melenovsky V, Hwang SJ, Lin G, Redfield MM, Borlaug BA. Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J. 2014;35(48):3452–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296–301.

    Article  CAS  PubMed  Google Scholar 

  37. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477–82.

    Article  CAS  PubMed  Google Scholar 

  38. Hiremath J, Thanikachalam S, Parikh K, Shanmugasundaram S, Bangera S, Shapiro L, et al. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant. 2010;29(2):137–49.

    Article  PubMed  Google Scholar 

  39. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800–4.

    Article  PubMed  Google Scholar 

  40. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915–22.

    Article  CAS  PubMed  Google Scholar 

  41. Lopez-Medrano F, Fernandez-Ruiz M, Ruiz-Cano MJ, Barrios E, Vicente-Hernandez M, Aguado JM, et al. High incidence of bloodstream infection due to gram-negative bacilli in patients with pulmonary hypertension receiving intravenous treprostinil. Arch Bronconeumol. 2012;48(12):443–7.

    Article  PubMed  Google Scholar 

  42. Jing ZC, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013;127(5):624–33.

    Article  CAS  PubMed  Google Scholar 

  43. Tapson VF, Jing ZC, Xu KF, Pan L, Feldman J, Kiely DG, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest. 2013;144(3):952–8.

    Article  CAS  PubMed  Google Scholar 

  44. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–33.

    Article  CAS  PubMed  Google Scholar 

  45. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358(9288):1119–23.

    Article  CAS  PubMed  Google Scholar 

  46. Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371(9630):2093–100.

    Article  CAS  PubMed  Google Scholar 

  47. Humbert M, Barst RJ, Robbins IM, Channick RN, Galie N, Boonstra A, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24(3):353–9.

    Article  CAS  PubMed  Google Scholar 

  48. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896–903.

    Article  CAS  PubMed  Google Scholar 

  49. Galie N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114(1):48–54.

    Article  CAS  PubMed  Google Scholar 

  50. D’Alto M, Vizza CD, Romeo E, Badagliacca R, Santoro G, Poscia R, et al. Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect. Heart. 2007;93(5):621–5.

    Article  PubMed  Google Scholar 

  51. Galie N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46(3):529–35.

    Article  CAS  PubMed  Google Scholar 

  52. Pulido T, Adzerikho I, Channick RN, Delcroix M, Galie N, Ghofrani HA, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–18.

    Article  CAS  PubMed  Google Scholar 

  53. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–57.

    Article  CAS  PubMed  Google Scholar 

  54. Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894–903.

    Article  CAS  PubMed  Google Scholar 

  55. Ghofrani HA, D’Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319–29.

    Article  CAS  PubMed  Google Scholar 

  56. Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330–40.

    Article  CAS  PubMed  Google Scholar 

  57. Galie N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D60–72.

    Article  PubMed  Google Scholar 

  58. McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S, et al. Treatment goals of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D73–81.

    Article  PubMed  Google Scholar 

  59. Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834–44.

    Article  CAS  PubMed  Google Scholar 

  60. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984;70(4):580–7.

    Article  CAS  PubMed  Google Scholar 

  61. Preston IR, Roberts KE, Miller DP, Sen GP, Selej M, Benton WW, et al. Effect of Warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the registry to evaluate early and long-term PAH disease management (REVEAL). Circulation. 2015;132(25):2403–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Olsson KM, Delcroix M, Ghofrani HA, Tiede H, Huscher D, Speich R, et al. Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). Circulation. 2014;129(1):57–65.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, 2nd Floor CVC / SPC 5853, 1500 E. Medical Center Dr., Ann Arbor, MI, 48109-5853, USA

    Victor M. Moles & Vallerie V. McLaughlin

Authors
  1. Victor M. Moles
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vallerie V. McLaughlin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Victor M. Moles.

Ethics declarations

Conflict of Interest

Drs Moles and McLaughlin have no conflicts of interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Additional information

Topical Collection on Women and Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moles, V.M., McLaughlin, V.V. Pulmonary Hypertension in Women: What Does the Cardiologist Need to Know?. Curr Cardiovasc Risk Rep 11, 10 (2017). https://doi.org/10.1007/s12170-017-0535-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s12170-017-0535-8

Keywords

Search

Navigation